Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (TNGX) is a biotechnology company focused on developing targeted cancer therapies. The company leverages genetic and genomic research to identify vulnerabilities in cancer cells, aiming to create precision medicines that selectively attack tumors while minimizing effects on normal tissue. Founded with a focus on innovative and personalized cancer treatments, Tango Therapeutics is engaged in the discovery and development of novel therapeutic candidates.
Company News
Tango Therapeutics' CEO Barbara Weber will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference, presenting a live webcast about the company's precision medicine cancer research.
Tango Therapeutics reported a steep decline in Q2 2025 revenue and wider net losses, with ongoing clinical trials in targeted oncology therapies and the early termination of its Gilead partnership.
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Analysts' ratings for Tango Therapeutics (NASDAQ:TNGX) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewha...
Best penny stocks to buy this week according to insiders. The post Best Penny Stocks To Buy Now? 3 With Heavy Insider Trading In October appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.